Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"

P.M. Ridker, J.G. MacFadyen, Børge G Nordestgaard, W. Koenig, J.J.P. Kastelein, J. Genest, R.J. Glynn, Paul M Ridker, Jean G Macfadyen, Wolfgang Koenig, John J P Kastelein, Jacques Genest, Robert J Glynn

    53 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk"'. Together they form a unique fingerprint.

    Medicine & Life Sciences